Ga direct naar de inhoud

Ga direct naar de navigatie

Uitgave van

Archief voor de categorie ‘Jurisprudentie’

In the midst of a deadly opioid crisis, Ohio sues drugmakers for marketing fraud

After seeing drug overdoses become the state’s leading cause of accidental deaths, officials in Ohio have had enough. In a new lawsuit filed on Wednesday, Ohio’s attorney general is going after Teva, Allergan, Johnson & Johnson, Purdue and Endo for alleged “fraudulent marketing practices” on powerful opioid painkillers.

Bron: FiercePharma Meer lezen »

Novo Nordisk reaches whistleblower settlement in ‘white-coat’ sales scheme lawsuit

Novo Nordisk has moved to settle a whistleblower lawsuit alleging the company ran a “white-coat marketing scheme” to pump up sales of NovoLog, Victoza and Levemir. According to the suit —recently unsealed as part of the settlement process—Novo Nordisk partnered with a clinical education company, Healthstar’s PT, to set up a program dubbed Changing Life with […]

Bron: FiercePharma Meer lezen »

GSK launches patent infringement action against Pfizer

GlaxoSmithKline has filed a patent infringement lawsuit against rival Pfizer over the alleged copying of its popular meningococcal group B vaccine Bexsero.  

Bron: InPharm.com Meer lezen »

Sanofi naar rechter om patenten diabetesmedicatie

De Franse farmaceut Sanofi beticht zijn Amerikaanse branchegenoot Merck van schending van patenten op diabetesmedicijnen. Het bedrijf heeft daarover een rechtszaak aangespannen in de Verenigde Staten, maakte het maandag bekend.

Bron: Skipr Meer lezen »

FDA to review MSD’s Keytruda as a first-line lung cancer treatment

The US Food and Drug Administration has accepted the supplemental biologics license application from MSD, known as Merck in the US and Canada, for Keytruda (pembrolizumab) as a first-line treatment for patients with advanced non-small cell lung cancer.

Bron: InPharm.com Meer lezen »

Boost for Clovis as FDA grants priority review for rucaparib in ovarian cancer

Clovis Oncology has announced that the US Food and Drug Administration has accepted its new drug application for rucaparib, and granted it priority review, for patients with advanced ovarian cancer.  

Bron: InPharm.com Meer lezen »

FDA delays appraisal of Sanofi, Zealand diabetes drug just days before decision due

There was unfortunate news for Sanofi and Zealand Pharma as the FDA announced that it required additional information, constituting a major amendment to the new drug application, for iGlarLixi.  

Bron: InPharm.com Meer lezen »

Celator receives FDA breakthrough therapy designation for leukaemia drug

A new treatment for acute myeloid leukaemia and other blood cancers from Celator Pharmaceuticals has been granted breakthrough therapy designation from the US Food and Drug Administration (FDA).

Bron: InPharm.com Meer lezen »

Johnson & Johnson hit with $55 million verdict in talc-powder trial

Johnson & Johnson was ordered by a U.S. jury on Monday to pay $55 million to a woman who said that using the company’s talc-powder products for feminine hygiene caused her to develop ovarian cancer.

Bron: Reuters Meer lezen »

Whistleblower accuses Novartis of paying bribes to push sales

An anonymous whistleblower has accused Swiss drugmaker Novartis of paying bribes in Turkey through a consulting firm to push drug sales, according to a Reuters report. The company secured advantages worth an estimated $85 million (£59 million) and the bribes were paid through a consulting firm, the report said.

Bron: InPharm.com Meer lezen »

« Oudere artikelen |